These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9349694)

  • 1. The clinical evaluation of cancer prevention agents.
    Goodman GE
    Proc Soc Exp Biol Med; 1997 Nov; 216(2):253-9. PubMed ID: 9349694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future.
    Omenn GS
    Eur J Cancer Prev; 2007 Jun; 16(3):184-91. PubMed ID: 17415088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Criteria for implementation of large and multiagent clinical chemoprevention trials.
    Meyskens FL
    J Cell Biochem Suppl; 2000; 34():115-20. PubMed ID: 10762023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition).
    Gray J; Mao JT; Szabo E; Kelley M; Kurie J; Bepler G;
    Chest; 2007 Sep; 132(3 Suppl):56S-68S. PubMed ID: 17873160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of lung cancer: the beta-Carotene and Retinol Efficacy Trial (CARET) in high-risk smokers and asbestos-exposed workers.
    Omenn GS; Goodman G; Thornquist M; Barnhart S; Balmes J; Cherniack M; Cullen M; Glass A; Keogh J; Liu D; Meyskens F; Perloff M; Valanis B; Williams J
    IARC Sci Publ; 1996; (136):67-85. PubMed ID: 8791118
    [No Abstract]   [Full Text] [Related]  

  • 6. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers.
    Omenn GS; Goodman G; Thornquist M; Grizzle J; Rosenstock L; Barnhart S; Balmes J; Cherniack MG; Cullen MR; Glass A
    Cancer Res; 1994 Apr; 54(7 Suppl):2038s-2043s. PubMed ID: 8137335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.
    Omenn GS; Goodman GE; Thornquist MD; Balmes J; Cullen MR; Glass A; Keogh JP; Meyskens FL; Valanis B; Williams JH; Barnhart S; Cherniack MG; Brodkin CA; Hammar S
    J Natl Cancer Inst; 1996 Nov; 88(21):1550-9. PubMed ID: 8901853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of lung cancer: the rise and demise of beta-carotene.
    Omenn GS
    Annu Rev Public Health; 1998; 19():73-99. PubMed ID: 9611613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET).
    Neuhouser ML; Patterson RE; Thornquist MD; Omenn GS; King IB; Goodman GE
    Cancer Epidemiol Biomarkers Prev; 2003 Apr; 12(4):350-8. PubMed ID: 12692110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New agents for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet RA; Doody LA; Malone WF; Hawk ET; Sigman CC
    J Cell Biochem Suppl; 1996; 26():1-28. PubMed ID: 9154166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiagent chemopreventive agent combinations.
    Brenner DE
    J Cell Biochem Suppl; 2000; 34():121-4. PubMed ID: 10762024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of cancer--focusing on clinical trials.
    Kakizoe T
    Jpn J Clin Oncol; 2003 Sep; 33(9):421-42. PubMed ID: 14594936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives.
    Goodman GE
    Cancer Res; 1992 May; 52(9 Suppl):2752s-2757s. PubMed ID: 1563007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of lung cancer.
    Goodman GE
    Crit Rev Oncol Hematol; 2000 Mar; 33(3):187-97. PubMed ID: 10789492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy trial.
    Challem JJ
    J Natl Cancer Inst; 1997 Feb; 89(4):325-6. PubMed ID: 9048840
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemoprevention trials and surrogate end point biomarkers in the cervix.
    Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
    Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.